We help biotech leaders build payer strategy into clinical development and prepare for BD partnering. Payer strategy answers the critical questions on pricing, reimbursement coverage, patient access, and payer evidence most likely to affect asset value.
In clinical development, payer value helps prioritize assets, indications and populations. This avoids the “approvable but not reimbursable” crisis. Phase 1 to 3 trial design and evidence planning for payer value are much less costly when strategized early.
Our pharma BD expertise helps position your asset value for BD fundraising, partnering, licensing and acquisition.
Three Payer Questions
Price
What is the asset’s price potential? Today’s price benchmarks may not reflect an asset future value. Many biotech teams use incorrect price assumptions.
Reimbursement Coverage
Who pays for this treatment? Is this reimbursable? How would payers cover, restrict, or value the treatment?
Access
What restrictions would significantly limit patient access and uptake? How can these be mitigated in phase 1-3 clinical trial design and evidence planning?
Why is Payer Strategy Important
BD Partnering
Strengthen the investor narrative, valuation assumptions, and have clear answers on price, reimbursement and payer risk.
Clinical planning
Align the TPP, population, trial design, comparator, endpoints, and evidence plan with payer value before trial decisions are locked.
Strategic Focus
Prioritize the assets, indications, and populations with the highest payer value to invest in.
Who We Help
We work with emerging biotech leadership teams that need Payer strategy to support BD investor partnering, and integrate into clinical development strategy to optimize asset value.
Best fit: Preclinical and clinical phase 1–3 biotechs with upcoming milestone to prioritize indication, optimize trial-design, or prepare for BD partnering and fundraising.
Typical needs include Payer strategy with defensible price and access assumptions, payer-ready diligence materials, a TPP and evidence plan that support reimbursement, and a practical access roadmap before key decisions are locked.
How We Help
Payer Readiness Identify price, access, evidence, and investor risks early.
Payer Strategy Define the price & access strategy and payer evidence roadmap.
Strategy Validation Pressure-test the TPP, value proposition, and access strategy.
Why Access Navigate
Founder-led payer strategy with a pharma BD perspective for stronger clinical development and BD asset valuation.
Access Navigate is founded and led by Sam Ang, a payer strategy and biopharma BD advisor with more than 20 years of experience across pricing, reimbursement, market access, and commercial BD evaluation. He has advised on over 100 pharma BD licensing and acquisition assessments, with single- and multi-asset deals ranging from USD $300 million to $15 billion. Sam helps biotechs and investors build and test assets’ payer value where it matters.
